VACCINE COMPOSITIONS
The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LATA, James Paul LACY, Michael Joseph WARFIELD, Kelly Lyn LOOK, Jee Loon RUIZ, Christian Fernando |
| description | The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024374709A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024374709A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024374709A13</originalsourceid><addsrcrecordid>eNrjZBAJc3R29vRzVXD29w3wD_YM8fT3C-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRibG5ibmBpaOhsbEqQIAAkcfuw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>VACCINE COMPOSITIONS</title><source>esp@cenet</source><creator>LATA, James Paul ; LACY, Michael Joseph ; WARFIELD, Kelly Lyn ; LOOK, Jee Loon ; RUIZ, Christian Fernando</creator><creatorcontrib>LATA, James Paul ; LACY, Michael Joseph ; WARFIELD, Kelly Lyn ; LOOK, Jee Loon ; RUIZ, Christian Fernando</creatorcontrib><description>The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241114&DB=EPODOC&CC=US&NR=2024374709A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241114&DB=EPODOC&CC=US&NR=2024374709A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LATA, James Paul</creatorcontrib><creatorcontrib>LACY, Michael Joseph</creatorcontrib><creatorcontrib>WARFIELD, Kelly Lyn</creatorcontrib><creatorcontrib>LOOK, Jee Loon</creatorcontrib><creatorcontrib>RUIZ, Christian Fernando</creatorcontrib><title>VACCINE COMPOSITIONS</title><description>The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBAJc3R29vRzVXD29w3wD_YM8fT3C-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGhwUYGRibG5ibmBpaOhsbEqQIAAkcfuw</recordid><startdate>20241114</startdate><enddate>20241114</enddate><creator>LATA, James Paul</creator><creator>LACY, Michael Joseph</creator><creator>WARFIELD, Kelly Lyn</creator><creator>LOOK, Jee Loon</creator><creator>RUIZ, Christian Fernando</creator><scope>EVB</scope></search><sort><creationdate>20241114</creationdate><title>VACCINE COMPOSITIONS</title><author>LATA, James Paul ; LACY, Michael Joseph ; WARFIELD, Kelly Lyn ; LOOK, Jee Loon ; RUIZ, Christian Fernando</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024374709A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>LATA, James Paul</creatorcontrib><creatorcontrib>LACY, Michael Joseph</creatorcontrib><creatorcontrib>WARFIELD, Kelly Lyn</creatorcontrib><creatorcontrib>LOOK, Jee Loon</creatorcontrib><creatorcontrib>RUIZ, Christian Fernando</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LATA, James Paul</au><au>LACY, Michael Joseph</au><au>WARFIELD, Kelly Lyn</au><au>LOOK, Jee Loon</au><au>RUIZ, Christian Fernando</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>VACCINE COMPOSITIONS</title><date>2024-11-14</date><risdate>2024</risdate><abstract>The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 μg to about 300 μg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2024374709A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | VACCINE COMPOSITIONS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A32%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LATA,%20James%20Paul&rft.date=2024-11-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024374709A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |